Tesofensine

Safety profile — read this first

Evidence tier: 1 — Phase 2 RCT data documents the monoaminergic AE profile; the cardiovascular and mood concerns are class-consistent with serotonin-norepinephrine-dopamine reuptake inhibition.

We lead with safety because Tesofensine's adverse-event profile is the dominant factor in its regulatory abandonment and the primary consideration for patients evaluating off-label compounded supply.

Tesofensine is a triple monoamine reuptake inhibitor (serotonin, norepinephrine, dopamine). The pharmacology is mechanistically related to older anorectic agents (sibutramine, phentermine) and to certain antidepressants and ADHD medications, with the monoaminergic CNS profile producing a predictable set of class-consistent adverse effects:

• Cardiovascular effects. The Phase 2 trial (Astrup 2008) documented dose-dependent heart rate elevation of approximately 7-8 bpm at the higher doses. Blood pressure increase was modest at the lower doses but more pronounced at 1.0 mg. Patients with hypertension or cardiovascular disease are at meaningful additional risk.
• Mood and psychiatric effects. Insomnia, agitation, anxiety, and changes in mood are documented in the Phase 2 dataset and are class-typical of monoamine-reuptake inhibitors. The Phase 3 program was abandoned in part due to concerns about the mood-effect signal.
• Stimulant-class effects. Dry mouth, constipation/diarrhea, headache, and reduced appetite (the intended effect) constitute the most common adverse events. Tolerability profile is class-consistent with stimulant-anorectic agents.
• Discontinuation considerations. Monoaminergic agents typically require tapered discontinuation rather than abrupt cessation; abrupt withdrawal from chronic tesofensine has not been systematically studied.

Patients with hypertension, cardiovascular disease, history of mood or anxiety disorder, prior stimulant intolerance, MAOI use, serotonergic medications, or seizure disorder should not consider tesofensine. The molecule's monoaminergic profile makes drug-drug interactions a meaningful consideration that requires clinician oversight rather than self-experimentation.

Mechanism

Evidence tier: 4 — Receptor pharmacology characterized in preclinical work; downstream behavioral and weight-loss effects measured in human RCTs.

Tesofensine is a synthetic small molecule that inhibits the presynaptic reuptake of dopamine, norepinephrine, and serotonin with relatively balanced potency across the three monoamine transporters. The molecule was originally developed by NeuroSearch (Denmark) as a candidate for Alzheimer's disease and Parkinson's disease — clinical development for those indications failed, but the weight-loss signal observed in the trials motivated the obesity-development program.

The proposed weight-loss mechanism is central appetite suppression via dopamine/norepinephrine-mediated satiety signaling, with serotonergic contribution to mood and anxiety modulation. The pharmacological profile overlaps with sibutramine (now withdrawn for cardiovascular safety concerns) and phentermine (FDA-approved with cardiovascular warnings). Recent work has suggested tesofensine may also silence GABAergic neurons in the lateral hypothalamus, an additional appetite-regulation mechanism beyond the classic monoamine-reuptake profile.

Mechanistically, tesofensine is not a peptide — it is a small molecule with chemical structure unrelated to peptide pharmacology. Its inclusion in peptide-research directories reflects its place in the off-label compounded weight-loss marketplace alongside the GLP-1 peptides, rather than its molecular biology.

Typical protocols

Evidence tier: 1 for trial doses; 5 for compounded community use.

The Phase 2 TIPO-1 trial (Astrup 2008) used 0.25 mg, 0.5 mg, and 1.0 mg orally once daily for 24 weeks. The 0.5 mg dose was identified as the primary candidate dose balancing efficacy with tolerability for the abandoned Phase 3 program. The 1.0 mg dose produced larger weight loss but with more significant cardiovascular and psychiatric AEs.

Compounded tesofensine is currently available in Mexico (where it has regulatory approval as Tesomet/Tesogen for obesity) and through some US compounding pathways on a research-use framing. Community-circulated protocols typically describe 0.25-0.5 mg once daily, with cycle lengths of 12-24 weeks, often combined with metformin in stacked protocols. These protocols extrapolate from the Phase 2 dose-finding work, not from a registered indication.

Dosing higher than 0.5 mg per day amplifies the cardiovascular and psychiatric AE profile substantially. Patients on tesofensine should have baseline and on-treatment blood pressure and heart rate monitoring; any prescribing clinician should treat this as a clinically significant intervention requiring active monitoring, not a casual off-label adjunct.

Evidence by indication

Evidence tier: 1 for Phase 2 obesity data; no Phase 3 readout exists.

Obesity (TIPO-1 Phase 2, Astrup 2008 PMID 18954574): The 24-week Phase 2 trial in 203 obese subjects on a calorie-restricted diet showed dose-dependent weight loss: 4.5% at 0.25 mg, 9.2% at 0.5 mg, 10.6% at 1.0 mg, vs 2.0% on placebo. This was a substantially larger weight-loss effect than was available from other oral weight-loss agents at the time and motivated NeuroSearch's Phase 3 program plans.

Phase 3 development (abandoned 2010): NeuroSearch initiated planning for Phase 3 but abandoned development in 2010 amid concerns about the cardiovascular and psychiatric AE profile and the broader regulatory environment for monoaminergic anorectics following sibutramine's withdrawal for cardiovascular safety. The company subsequently divested the program; Saniona acquired and partially advanced tesofensine for narrower indications.

Mexican obesity approval: Tesofensine + metformin (Tesomet) received regulatory approval in Mexico for obesity, where it is the basis for the compounded supply that has migrated into the US off-label market.

Other indications (Alzheimer's, Parkinson's, hypothalamic obesity): Earlier development for Alzheimer's disease and Parkinson's disease failed to demonstrate clinical efficacy. More recent work on hypothalamic obesity (post-craniopharyngioma) has shown more promising signals in small studies.

The honest framing: tesofensine has Phase 2 weight-loss data that exceeds most oral weight-loss agents, but the molecule was abandoned by its original developer at the Phase 2/3 transition due to AE concerns, did not complete Phase 3, and is not FDA-approved. The compounded supply circulating in the US market is operating outside the FDA approval pathway.

Where it fits relative to alternatives

Evidence tier: 5 — Editorial positioning.

In the weight-loss pharmacotherapy hierarchy as of 2026:

• Semaglutide (Wegovy, FDA-approved): ~15% weight loss, RCT-grade evidence
• Tirzepatide (Zepbound, FDA-approved): ~22% weight loss, RCT-grade
• Retatrutide (Phase 3): ~24-29% weight loss
• Orforglipron (Phase 3, oral): ~12-15% weight loss
• CagriSema (Phase 3 complete): ~22.7% weight loss
• Tesofensine: Phase 2 ~9-11% weight loss, abandoned Phase 3, compounded supply only
• AOD-9604: Failed Phase 2b, no validated indication
• Phentermine (FDA-approved): Short-term use, cardiovascular warnings, related monoaminergic mechanism

Tesofensine's specific positioning is "the monoaminergic oral weight-loss agent with Phase 2 efficacy that didn't make it through Phase 3." For patients seeking validated weight-loss pharmacotherapy, the GLP-1-class options are categorically better-evidenced choices — they have completed Phase 3, are FDA-approved, have established cardiovascular safety profiles (and in semaglutide's case, demonstrated CV benefit in SELECT PMID 37952131), and operate on a mechanism (incretin/satiety) that does not carry the cardiovascular and psychiatric AE profile of monoamine-reuptake inhibition.

There is no clinical scenario where compounded tesofensine is the preferred choice over an FDA-approved GLP-1-class agent in 2026.

Regulatory status + access

Evidence tier: 5 — Regulatory-process content.

Tesofensine is not FDA-approved in the United States. It has regulatory approval in Mexico (Tesomet/Tesogen, primarily as a combination with metformin) for obesity. The molecule is not on the FDA bulks list for compounding, though some 503A pharmacies have supplied compounded tesofensine on a research-use framing — this is regulatorily distinct from compounded GLP-1 peptides (which are based on FDA-approved molecules in shortage status). WADA does not currently list tesofensine specifically. Patients considering tesofensine should discuss the abandoned Phase 3 development and the FDA-approved GLP-1-class alternatives with a clinician before pursuing compounded or international supply. The cardiovascular and psychiatric monitoring requirements for ongoing tesofensine use are non-trivial and require clinician oversight.

References

• Astrup A, Madsbad S, Breum L, et al. 2008. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. PMID 18954574
• Wilding JPH, Batterham RL, Calanna S, et al. 2021. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. PMID 33567185 — cited as RCT-grade FDA-approved alternative.
• Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. 2023. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. PMID 37952131 — cited for cardiovascular-benefit context against tesofensine's cardiovascular-risk profile.

Limitations

This page does not constitute medical advice. Tesofensine has a documented monoaminergic AE profile that includes cardiovascular and psychiatric risks — patients with hypertension, cardiovascular disease, mood or anxiety disorder history, serotonergic medication use, MAOI use, or seizure disorder should not consider this molecule. The Phase 3 abandonment by NeuroSearch reflected legitimate safety concerns that have not been resolved by subsequent development. Patients seeking weight-loss pharmacotherapy in 2026 have FDA-approved GLP-1-class options with categorically better evidence and safety profiles; tesofensine sits outside the validated pharmacotherapy landscape. We would update our framing if a well-powered Phase 3 trial of tesofensine were conducted and read out positively, or if a new safety signal emerged from real-world compounded use that warranted regulatory attention.